Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Glycopyrronium bromide 350micrograms/5ml oral liquid
0102000L0AAAMAM
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 400micrograms/5ml oral liquid
0102000L0AAANAN
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 600micrograms/5ml oral liquid
0102000L0AAAGAG
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 640micrograms/5ml oral solution
0102000L0AABMBM
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 650micrograms/5ml oral liquid
0102000L0AAATAT
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 800micrograms/5ml oral liquid
0102000L0AAARAR
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 80micrograms/5ml oral liquid
0102000L0AAAPAP
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 900micrograms/5ml oral solution
0102000L0AABSBS
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
|
Glycopyrronium bromide 900micrograms/5ml oral suspension
0102000L0AABRBR
|
Glycopyrronium bromide (Oral) | Glycopyrronium bromide | Gastro-Intestinal System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.